Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4PVDY)

Drug Name

Durvalumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Urothelial carcinoma	2C92.0	Approved	[1]
Hepatocellular carcinoma	2C12.02	Phase 3	[2]
Biliary tract cancer	2C17	Phase 2	[2]
Melanoma	2C30	Phase 2	[2]
Pancreatic ductal carcinoma	2C10.0	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Diffuse large B-cell lymphoma	2A81	Phase 1	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Urothelial carcinoma

ICD Disease Classification

2C92.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death 1 ligand 1 (PD-L1)	DTT	CD274	4.38E-07	0.37	2.1

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.